Disease · MONDO_0005459

human African trypanosomiasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. human African trypanosomiasis. Diseases, record MONDO_0005459. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005459

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: human African trypanosomiasis; Open Targets
Open Targets ID: MONDO_0005459; Open Targets
Other names: Africam sleeping sickness, African trypanosomiasis, HAT, sleeping sickness; Open Targets
Disease Ontology: DOID:10112; Disease Ontology
MeSH: D014353; MeSH
NCI Thesaurus: C84541; NCI Thesaurus
Orphanet: ORPHA:3385; Orphanet
Highest stage of its drugs: Approval, for 2 of its 9 drugs, from FDA and TTD; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FEXINIDAZOLE	CHEMBL1631694	Small molecule	Approval	FDA and TTD	8	5	5	Drugs and targets
EFLORNITHINE	CHEMBL830	Small molecule	Approval	TTD	5	4	4	Drugs and targets
NIFURTIMOX	CHEMBL290960	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
MELARSOPROL	CHEMBL166	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ACOZIBOROLE	CHEMBL2347704	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
PAFURAMIDINE	CHEMBL319669	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PAFURAMIDINE MALEATE	CHEMBL2107359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTAMIDINE	CHEMBL55	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SURAMIN	CHEMBL265502	Small molecule	Phase 1	TTD	2	0	0	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FGF1	Fibroblast growth factor 1	1	Acidic fibroblast growth factor inhibitor	Phase 1	https://conductscience.org/library/genes/2246	Drugs and targets
ODC1	Ornithine decarboxylase	1	Ornithine decarboxylase inhibitor	Approval	https://conductscience.org/library/genes/4953	Drugs and targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03087955	Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense	Phase 2/3	208	2025-09-17	Trypanosomiasis, African, Gambiense Trypanosomiasis, Sleeping Sickness	ACOZIBOROLE	Its record names the disease	ClinicalTrials.gov
NCT03025789	Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage	Phase 3	174	2024-06-07	Trypanosomiasis, African, Sleeping Sickness, Trypanosomiasis; Gambian	FEXINIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03974178	Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense	Phase 2/3	45	2025-01-30	Trypanosomiasis, African, Sleeping Sickness, Trypanosoma Brucei Rhodesiense; Infection	FEXINIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00330148	Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis	Phase 3	435		Trypanosomiasis, African	EFLORNITHINE, MELARSOPROL, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT01685827	Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2	Phase 2/3	394		Human African Trypanosomiasis (HAT), Sleeping Sickness	EFLORNITHINE, FEXINIDAZOLE, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT00146627	Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis	Phase 3	280		Trypanosomiasis, African	EFLORNITHINE, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT02169557	Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study	Phase 2/3	230		Human African Trypanosomiasis (HAT)	FEXINIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02184689	Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study	Phase 2/3	125		Human African Trypanosomiasis (HAT)	FEXINIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00803933	Trial of DB289 for the Treatment of Stage I African Trypanosomiasis	Phase 2	111		African Trypanosomiasis	PAFURAMIDINE MALEATE, PENTAMIDINE	Its record names the disease	ClinicalTrials.gov
NCT00489658	Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda	Phase 2/3	31		Trypanosomiasis, African	EFLORNITHINE, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Late-stage HAT vs Early- and Intermediate-stage HAT: deaths from any cause	4 of 167	0 of 41	208	NCT03087955	Trial comparisons
Late-stage HAT vs Early- and Intermediate-stage HAT: serious adverse events	18 of 167	3 of 41	208	NCT03087955	Trial comparisons
Inpatients vs Outpatients: Number of Participants With Any Temporary or Permanent Treatment Discontinuation (Inpatient or Outpatient) for Reasons Related to Safety	4 of 136	0 of 38	174	NCT03025789	Trial comparisons
Inpatients vs Outpatients: Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE)	10 of 136	4 of 38	174	NCT03025789	Trial comparisons
Inpatients vs Outpatients: Number of Participants With Any Grade ≥ 3 Treatment-emergent Adverse Events (AEs) Including Laboratory and Hematological Abnormalities (if Considered Clinically Significant)	10 of 136	4 of 38	174	NCT03025789	Trial comparisons
Inpatients vs Outpatients: Number of Participants With Any Permanent Treatment Discontinuation (Inpatient or Outpatient) for Reasons Related to Safety	1 of 136	0 of 38	174	NCT03025789	Trial comparisons
Inpatients vs Outpatients: deaths from any cause	1 of 136	0 of 38	174	NCT03025789	Trial comparisons
Inpatients vs Outpatients: serious adverse events	10 of 136	4 of 38	174	NCT03025789	Trial comparisons
Patients With Stage 1 r-HAT vs Patients With Stage 2 r-HAT: deaths from any cause	0 of 10	1 of 35	45	NCT03974178	Trial comparisons
Patients With Stage 1 r-HAT vs Patients With Stage 2 r-HAT: serious adverse events	0 of 10	3 of 35	45	NCT03974178	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36460027	RESULT	1	PubMed
19559476	RESULT	1	PubMed
40288400	DERIVED	1	PubMed
40288399	DERIVED	1	PubMed
36179736	DERIVED	1	PubMed
34143998	DERIVED	1	PubMed
29113731	DERIVED	1	PubMed
26881924	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005459

GET https://conductscience.org/api/diseases/v1/MONDO_0005459/drugs

API reference For AI assistants